Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 28;122(6):926–938. doi: 10.1055/s-0041-1740254

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ )

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.

PMC Copyright notice

Fig. 3 — Risk of recurrent venous thromboembolism (VTE), major bleeding, and clinically relevant nonmajor bleeding among patients with chronic kidney disease prescribed apixaban or warfarin to treat VTE, stratified by CKD stages. The figure shows a forest plot of the risks of recurrent VTE, major bleeding, and CRNMB. The patient population consisted of patients with CKD being treated for VTE with apixaban or warfarin during the study period, stratified by the stage of CKD (stage I/II, stage III, stage IV, stage V/ESRD). The number of events and the incidence per 100 person-years are listed for each outcome, stage, and treatment. Risk is indicated by an HR and 95% CI. The degree of risk is indicated along the x -axis. The p -value for interaction indicates the association between CKD stages and treatment effects on a specific outcome. Black squares indicate the hazard ratio; solid black lines indicate the 95% CI. CI, confidence interval; CKD, chronic kidney disease; CRNMB, clinically relevant nonmajor bleeding; ESRD, end-stage renal disease; HR, hazard ratio; VTE, venous thromboembolism. ^a < 11 used due to agreements with commercial providers to assure privacy for very small number of events; interaction is significant if p < 0.10.